Antibodies produced by SARS-CoV-2 variants differ in their ability to neutralise other variants of the virus, according to research by UCLH and the Francis Crick Institute.
Over the course of the pandemic, various COVID-19 variants have arisen with the Delta variant currently dominant in the UK. Understanding how some variants may be able to trigger an effective antibody response against other variants, in addition to themselves, could help inform future vaccine design.
In their study, published in eLife (29 July), the researchers analysed blood samples collected from patients who had previously been infected with COVID-19 and who were admitted to UCLH for other reasons, as well as samples collected from patients at different points earlier in the pandemic. They identified COVID-19 antibodies in the blood, and in the lab ran tests to see if antibodies produced after infection with one variant were able to bind to and neutralise other variants.
The study included:
- The original strain first discovered in Wuhan, China
- The dominant strain in Europe during the first wave in April 2020 (D614G)
- B.1.1.7, the variant first discovered in Kent, UK (Alpha)
- B.1.351, the variant first discovered in South Africa (Beta)
While antibodies produced by one variant were able to bind to other variants at a similar rate, there were some differences in whether antibodies could neutralise other variants. If an antibody is able to neutralise a virus, this means it can stop the virus from entering the hosts cells in order to replicate.
The researchers found that antibodies produced by the Alpha variant were not able to neutralise the original or D614G strains as effectively, in comparison to neutralising the Alpha variant itself.
Antibodies produced against infection with the D614G strain were able to neutralise both the Alpha and original strains to a similar level as D614G.
Both the Alpha and D614G strains produced antibodies which were not able to effectively neutralise the Beta strain.
There are many elements of the immune system which impact how protected an individual may be against future disease. This includes memory B cells and T cells which equip the immune system to deal with evolving threats. As a result, these findings do not necessarily mean people who were infected with specific variants are less protected against others.
Kevin Ng, co-first author and PhD student in the Retroviral Immunology Laboratory at the Crick says: “It’s important to note that most people who have been infected with the virus will not know which variant they were infected with and it is critical that everyone eligible for the vaccine takes up the opportunity because we know they are effective in some way against all known variants.”
As the antibodies were able to bind to other variants at a similar level, but had differing ability to neutralise other strains, this suggests that there are only a few regions on the spike of the virus which are important to this neutralisation process. It is the mutations within these key sites which impact the ability of antibodies produced by one variant to neutralise another.
Nikhil Faulkner, co-first author and PhD student in the Retroviral Immunology Laboratory at the Crick says: “As the pandemic continues and more variants may arise, research into how infection with one variant impacts immune responses to other variants is important.
“This could help inform experts who are studying and deciding which variants should be included in future booster vaccines. By creating a multivalent vaccine, like with the annual flu shot, we could factor different variants into a single vaccine. This would help to increase the breadth of immune protection against current and future variants.”